Mid-term effect of balloon aortic valvuloplasty on mitral regurgitation in aortic stenosis

Table 3 Time Course of Parameters after BAV in the Non-MR Group

	Baseline	1 month after BAV	P value	3 months after BAV	P value
Clinical data
NYHA III/IV, n (%)	19 (44.2)	2 (4.5)	< 0.001	2 (4.5)	< 0.001
Laboratory data
BNP, pg/mL	216 (112–422)	201 (103–405)	0.293	171 (11–368)	0.086
Conventional echo parameters
LVEDD, mm	43.2 ± 7.1	42.8 ± 6.4	0.680	42.8 ± 6.4	0.659
LVESD, mm	28.9 ± 7.0	28.0 ± 6.9	0.230	27.4 ± 5.8	0.091
LVEF, %	58.6 ± 7.8	59.8 ± 8.8	0.318	61.4 ± 7.8	0.024
LVSVI, mL	44.7 ± 13.2	49.0 ± 13.5	0.016	49.3 ± 14.7	0.009
E/A	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.435	0.7 (0.5–0.8)	0.610
E/e’	17.8 ± 7.8	17.5 ± 8.2	0.692	18.0 ± 9.9	0.918
TR-PG, mmHg	33.4 ± 12.1	31.2 ± 13.5	0.138	30.6 ± 11.4	0.151
AR ≥ moderate, n (%)	3 (7.0)	4 (9.5)	0.713	6 (14.0)	0.483
AS parameters
AVA, cm²	0.70 ± 0.15	0.88 ± 0.20	< 0.001	0.84 ± 0.20	< 0.001
AVAi, cm²/m²	0.48 ± 0.10	0.62 ± 0.14	< 0.001	0.59 ± 0.13	< 0.001
Peak V, m/s	69.1 ± 27.0	53.1 ± 23.1	< 0.001	57.0 ± 23.8	0.001
mPG (mmHg)	39.1 ± 15.6	30.9 ± 14.2	< 0.001	32.5 ± 14.3	< 0.001
MR parameters
MR jet area, cm²	1.0 (0.3–2.5)	0.7 (0.2–1.8)	0.627	0.9 (0.3–2.1)	0.943
%MR, %	7.3 (2.0–12.9)	4.9 (1.2–11.3)	0.472	4.1 (1.7–12.2)	0.801
Mitral annular dimension, mm	25.8 ± 3.1	23.8 ± 3.4	0.001	24.7 ± 3.3	0.074
Tenting height, mm	3.6 ± 1.6	3.0 ± 1.5	0.047	3.0 ± 1.7	0.052
Tenting area, mm²	46.9 ± 24.0	36.5 ± 21.1	0.015	37.9 ± 25.9	0.052

Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
Abbreviations as in Table 1

ISSN: 1476-7120